Clinical trial
Safety and Antifungal Activity of Recombinant Interferon-Gamma 1b (rIFN-Gamma…
NCT00012467 · InterMune, Industry · Completed
Key facts
| NCT number | NCT00012467 |
|---|---|
| Title | Safety and Antifungal Activity of Recombinant Interferon-Gamma 1b (rIFN-Gamma 1b) Given With Standard Therapy in Patients With Cryptococcal Meningitis |
| Official title | A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Phase II Study of the Safety and Antifungal Activity of Subcutaneous Recombinant Interferon-Gamma 1b (rIFN-Gamma 1b) in Conjunction With Standard Therapy in Patients With Acute Cryptococcal Meningitis |
| Lead sponsor | InterMune, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Meningitis, Cryptococcal, HIV Infections |
| Intervention type | Drug |
| Interventions | Itraconazole, Flucytosine, Fluconazole, Amphotericin B, Interferon gamma-1b |
| Enrollment | 60 |
| Start date | Jan 1, 2000 |
| Completion | Jul 1, 2001 |
| First posted | Aug 31, 2001 |
| Last update posted | Jun 3, 2009 |
| Countries | Peru, United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: